Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Sunday, December 31, 2023 1 min read
Key Takeaway: AbbVie Inc. has updated its earnings guidance for the fourth quarter and full-year ended December 31, 2023. The guidance now accounts for acquired IPR D and milestones expenses, which have led to a reduction in the adjusted diluted EPS range. Specifically, the adjusted diluted EPS is estimated to range between $2.72 to $2.76 for Q4 2023, down from previous estimates. Overall, the figures indicate a significant impact from these new expenses.
Market Sentiment Analysis
CONCERNS & RISKS
Q4 2023 guidance shows a decrease in adjusted diluted EPS due to acquired IPR D and milestones expenses.
The new guidance reflects potential uncertainties in achieving forecasted earnings.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended December 31, 2023
Full-Year Ended December 31, 2023
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q4 2023 acquired IPR D and milestones expense
$
-
$
2.87
$
2.91
$
496
$
11.19
$
11.23
Q4 2023 acquired IPR D and milestones expense
282
(0.15)
(0.15)
282
(0.15)
(0.15)
Guidance including Q4 2023 acquired IPR D and milestones expense
$
282
$
2.72
$
2.76
$
778
$
11.04
$
11.08
Frequently Asked Questions
What was the acquired IPR D expense for Q4 2023?
The acquired IPR D and milestones expense for Q4 2023 was $282 million.
What is the adjusted diluted EPS range for Q4 2023?
The adjusted diluted EPS range for Q4 2023 is $2.72 to $2.76.
What is the full-year acquired IPR D expense for 2023?
The full-year acquired IPR D and milestones expense for 2023 is $778 million.
How does Q4 2023 expense impact annual EPS?
Including Q4 2023 expenses, the full-year adjusted EPS is $11.04 to $11.08.
What was the previous guidance for adjusted diluted EPS?
The previously announced guidance for adjusted diluted EPS was $2.87 to $2.91.